吉米沙星（SB 265805，LB20304）对近期肺炎衣原体临床分离株的体外活性。
In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
作者信息
Roblin P M, Reznik T, Kutlin A, Hammerschlag M R
机构信息
Division of Infectious Diseases, Department of Pediatrics, Health Science Center at Brooklyn, State University of New York, Brooklyn, New York 11203, USA.
出版信息
Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806.
Abstract
We compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin.
摘要
我们比较了新型喹诺酮类抗生素吉米沙星与左氧氟沙星、莫西沙星、曲伐沙星、红霉素和强力霉素对20株肺炎衣原体的体外活性。吉米沙星是所测试的喹诺酮类药物中活性最强的，其90%分离株被抑制时的最低抑菌浓度（MIC）以及90%测试菌株被杀死时的最低杀菌浓度为0.25微克/毫升，但其活性低于强力霉素和红霉素。
相似文献
1
In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806.
2
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
3
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
J Antimicrob Chemother. 2001 May;47(5):681-4. doi: 10.1093/jac/47.5.681.
4
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Antimicrob Agents Chemother. 2000 Feb;44(2):304-10. doi: 10.1128/AAC.44.2.304-310.2000.
5
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
J Antimicrob Chemother. 2002 May;49(5):763-7. doi: 10.1093/jac/dkf029.
6
Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.
Int J Antimicrob Agents. 2003 Jun;21(6):574-7. doi: 10.1016/s0924-8579(03)00060-8.
7
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
8
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Antimicrob Agents Chemother. 2002 Feb;46(2):517-8. doi: 10.1128/AAC.46.2.517-518.2002.
9
Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:107-10. doi: 10.1093/jac/45.suppl_3.107.
10
Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:35-9. doi: 10.1093/jac/45.suppl_3.35.
引用本文的文献
1
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
2
Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes.
Antimicrob Agents Chemother. 2000 Nov;44(11):3193-5. doi: 10.1128/AAC.44.11.3193-3195.2000.
3
Gemifloxacin.
Drugs. 2000 May;59(5):1137-47; discussion 1148. doi: 10.2165/00003495-200059050-00009.
本文引用的文献
1
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
2
In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
3
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
Antimicrob Agents Chemother. 1997 Jan;41(1):204-11. doi: 10.1128/AAC.41.1.204.
4
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
5
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
Pediatr Infect Dis J. 1995 Jun;14(6):471-7. doi: 10.1097/00006454-199506000-00002.
6
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
7
Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.
J Clin Microbiol. 1992 Aug;30(8):1968-71. doi: 10.1128/jcm.30.8.1968-1971.1992.
8
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
Zotero 插件